Medical Imaging Innovator MolecuLight Secures $11.7 Million in Series B Funding Round for Further Growth and Innovation

MolecuLight Inc., a pioneering privately-owned medical imaging company, has successfully secured $11.7 million in its latest funding round. This significant investment will enable the company to further enhance its groundbreaking fluorescent imaging platform technology, which is set to transform multiple clinical markets. MolecuLight’s flagship products, the MolecuLight i:X® and DX™ fluorescence imaging systems, are already making waves in the global wound care market. These advanced point-of-care handheld imaging devices empower healthcare professionals to accurately detect wounds with elevated bacterial burdens—specifically those exceeding 10^4 CFU/g—through real-time imaging solutions, significantly improving patient outcomes. The latest funding will accelerate the commercialization efforts of these innovative devices, allowing for improved accessibility and utilization in frontline healthcare settings. Furthermore, the investment will support MolecuLight's ongoing research and development activities, enabling the company to explore additional applications for its technology in the healthcare landscape. As the demand for effective wound care solutions continues to rise, MolecuLight is poised to solidify its position as a leader in the field, ensuring that clinicians have the right tools to provide optimal care for patients suffering from wounds complicated by bacterial infections. This funding announcement marks an exciting milestone for MolecuLight and its commitment to advancing medical imaging technology while improving the standard of care in wound management and beyond. #moleculight